Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026
Merck announced it will present new data from its HIV pipeline at the upcoming AIDS 2026 conference, including late-breaker results from two pivotal Phase 3 trials evaluating its investigational once-weekly oral islatravir and lenacapavir regimen. The presentations will span daily, weekly, and monthly options, featuring Phase 2b data on islatravir combined with ulonivirine, long-term Phase 3 data on doravirine/islatravir, and early Phase 1 data on the monthly PrEP candidate MK-8527 (alimatravir).
Key figures
- Drug Name
- islatravir
- Phase Of Trial
- Phase 3
- Timepoints
- ["Week 48","Week 24","Week 96"]
- Trial identifiers
- ["ISLEND-1","ISLEND-2","MK-8591B-060"]
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.